Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most liver-adverse-effect and post-abnormal-LFT monitoring concepts align with Section 5.4, but several statements overreach beyond the label (e.g., asymptomatic routine findings, specific symptom examples, and increased risk with pre-existing hepatic impairment), and the label does not provide explicit holding/stopping thresholds or symptom-driven decision rules.
Category Scores
Accurate Statements
Tigecycline can cause liver enzyme abnormalities.
Section 5.4 (transaminases/increases in liver-related laboratory tests).
Tigecycline can cause increases in aminotransferases (ALT/AST).
Section 5.4 (transaminases).
Lab abnormalities can occur during tigecycline treatment.
Section 5.4 (abnormal liver function tests/laboratory abnormalities seen in treated patients).
Clinicians should reassess the regimen if liver abnormalities are found during tigecycline therapy.
Section 5.4 (evaluate risk/benefit of continuing tigecycline therapy).
Unsupported Statements
For many patients, elevated liver enzymes are detected on routine blood tests without obvious symptoms.
Section 5.4 does not describe routine testing frequency or that findings are typically asymptomatic in 'many patients'.
In some cases, patients may develop signs or symptoms of liver injury (e.g., jaundice or fatigue) during tigecycline treatment.
Section 5.4 mentions isolated significant hepatic dysfunction/hepatic failure and lab abnormalities, but does not explicitly provide these symptom examples.
Risk of liver injury/liver enzyme abnormalities with tigecycline can be higher in patients with pre-existing hepatic impairment.
Section 5.4 does not state increased risk tied to pre-existing hepatic impairment.
Risk can be higher with prolonged therapy and with multiple medications that affect the liver.
Section 5.4 notes some patients were receiving multiple concomitant medications, but does not state risk is higher with prolonged therapy.
Safety guidance supports checking and trending liver tests during tigecycline therapy.
Section 5.4 advises monitoring after abnormal liver function tests occur; it does not explicitly recommend routine scheduled checks or the specific concept of 'trending'.
The threshold for holding or stopping tigecycline depends on the magnitude of enzyme elevation and clinical context, such as symptoms of hepatitis or signs of worsening liver function.
Section 5.4 does not provide hold/stop thresholds or symptom-specific decision rules.
Contradictions
Important Omissions
Section 5.4 includes that hepatic dysfunction may occur after discontinuation of tigecycline; the claims provided do not address this temporal possibility.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overgeneralized statements about asymptomatic routine detection, specific symptom examples, increased risk with pre-existing hepatic impairment, and implied hold/stop thresholds are not supported by Section 5.4. These could lead to overspecified clinical actions beyond the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several key claims extend beyond Section 5.4 (risk-factor emphasis and symptom examples) and there are no label-supported hold/stop thresholds or routine/trending recommendations.
Suggested Improvement
Restrict liver-related statements to those explicitly described in Section 5.4: that bilirubin/PT/transaminases increases and isolated cases of significant hepatic dysfunction/hepatic failure have been reported; advise monitoring for evidence of worsening hepatic function and evaluating risk/benefit of continuing therapy when abnormal LFTs occur; avoid specifying routine asymptomatic detection, symptom examples, pre-existing hepatic impairment as a risk modifier, prolonged-therapy risk, and any hold/stop thresholds not stated in the label.